A Phase 3 interventional study of Evolocumab and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Amgen. Completed at 66 sites in 26 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 25th largest by enrollment, is one of 4 that started in 2016, is one of 22 in phase 3, and was the 23rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2016, is one of 22 in phase 3, and was the 23rd registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.
A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo, when added to standard of care, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching subcutaneous injection every 4 weeks (QM)
Drug: Placebo
Evolocumab subcutaneous injection QM
Drug: Evolocumab
Dose of subcutaneous evolocumab every 4 weeks
Also known as: AMG 145; EvoMab
Dose of subcutaneous placebo treatment every 4 weeks
Percent Change From Baseline to Week 24 in LDL-C
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from interactive voice response system \[IVRS\]), scheduled visit and the interaction of treatment with scheduled visit as covariates. The model uses an unstructured covariance.
Time frame: Baseline, Week 24
Mean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 22, Week 24
Change From Baseline to Week 24 in LDL-C
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 24
Percent Change From Baseline to Week 24 in Non-HDL-C
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates
Time frame: Baseline, Week 24
Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 24
Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 24
Percent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 24
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation (DC), Fatal TEAEs, and Device-Related TEAEs
An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. An SAE is defined as an adverse event that: is fatal; is a life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other medically important serious event. Events were graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grading scale (1=mild; 2=moderate; 3=severe; 4=life-threatening; 5=death). Events were defined as treatment emergent if they occurred after the first dose of study drug and up to and including 30 days after the last dose or the end of study date, whichever is earlier.
Time frame: From first dose of study drug up to and including 30 days after the last dose or end of study date (Week 24), whichever was earlier. Mean (SD) duration on study was 5.664 (0.278) and 5.608 (0.137) months for Placebo and EvoMab arms, respectively.
Number of Participants With Maximum Post-Baseline Laboratory Toxicities of Grade ≥ 3
Laboratory toxicity grading was based on NCI CTCAE grading. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity. Values representing a worsening from baseline are shown.
Time frame: Week 24
Change From Baseline Over Time in Systolic Blood Pressure
Time frame: Baseline, Week 4, Week 12, Week 20, Week 22, Week 24
Change From Baseline Over Time in Diastolic Blood Pressure
Time frame: Baseline, Week 4, Week 12, Week 20, Week 22, Week 24
Change From Baseline Over Time in Heart Rate
Time frame: Baseline, Week 4, Week 12, Week 20, Week 22, Week 24
Number of Participants Testing Positive for Anti-Evolocumab Antibodies
Time frame: up to Week 24
Serum Evolocumab Concentrations Over Time
Time frame: Week 12, Week 22, Week 24
Participants were enrolled from 24 March 2016 to 30 May 2019 at 8 research centers in North America, 30 research centers in Europe, 6 research centers in Latin America, and 3 research centers in Asia Pacific.
| Milestone | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Started | 53 | 105 |
| Randomized and dosed | 53 | 104 |
| Completed | 53 | 104 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from interactive voice response system \[IVRS\]), scheduled visit and the interaction of treatment with scheduled visit as covariates. The model uses an unstructured covariance.
| percent change | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 24 in LDL-C | -6.23 ± 3.08 | -44.53 ± 2.17 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Mean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C | -5.87 ± 2.66 | -47.95 ± 1.92 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
| mg/dL | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Change From Baseline to Week 24 in LDL-C | -9.0 ± 6.2 | -77.5 ± 4.4 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates
| percent change | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 24 in Non-HDL-C | -6.14 ± 2.87 | -41.19 ± 2.01 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB) | -2.37 ± 2.70 | -34.85 ± 1.88 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio | -4.66 ± 2.60 | -34.96 ± 1.82 |
Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio | -0.63 ± 2.80 | -37.02 ± 1.95 |
An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. An SAE is defined as an adverse event that: is fatal; is a life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other medically important serious event. Events were graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grading scale (1=mild; 2=moderate; 3=severe; 4=life-threatening; 5=death). Events were defined as treatment emergent if they occurred after the first dose of study drug and up to and including 30 days after the last dose or the end of study date, whichever is earlier.
| participants | Placebo | EvoMab 420 mg QM |
|---|---|---|
| All TEAEs | 34 | 64 |
| Grade ≥ 2 TEAEs | 22 | 46 |
| Grade ≥ 3 TEAEs | 0 | 4 |
| Grade ≥ 4 TEAEs | 0 | 0 |
| Serious TEAEs | 0 | 1 |
| TEAEs Leading to DC of Study Drug | 0 | 1 |
| Serious TEAEs Leading to DC of Study Drug | 0 | 0 |
| Non-Serious TEAEs Leading to DC of Study Drug | 0 | 1 |
| Fatal TEAEs | 0 | 0 |
| Device-Related TEAEs | 2 | 3 |
| Device-Related Grade ≥ 2 TEAEs | 0 | 0 |
| Device-Related Grade ≥ 3 TEAEs | 0 | 0 |
| Device-Related Grade ≥ 4 TEAEs | 0 | 0 |
| Serious Device-Related TEAEs | 0 | 0 |
Laboratory toxicity grading was based on NCI CTCAE grading. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity. Values representing a worsening from baseline are shown.
| participants | Placebo | EvoMab 420 mg QM |
|---|---|---|
| High Total Bilirubin - Grade 3 | 1 | 0 |
| High Total Cholesterol - Grade 3 | 1 | 1 |
| High Uric Acid - Grade 3 | 2 | 8 |
| mmHg | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Change at Week 4 | -0.1 ± 11.3 | -0.7 ± 9.4 |
| Change at Week 12 | -0.6 ± 10.3 | 0.3 ± 9.6 |
| Change at Week 20 | -2.1 ± 7.7 | 0.1 ± 10.1 |
| Change at Week 22 | 1.0 ± 10.9 | 1.1 ± 10.0 |
| Change at Week 24 | -0.6 ± 11.4 | 0.6 ± 10.7 |
| mmHg | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Change at Week 4 | -2.5 ± 9.5 | -1.5 ± 7.3 |
| Change at Week 12 | -2.2 ± 10.0 | 0.5 ± 8.9 |
| Change at Week 20 | -3.3 ± 7.6 | -0.6 ± 7.7 |
| Change at Week 22 | -1.5 ± 9.3 | 2.9 ± 8.0 |
| Change at Week 24 | -0.5 ± 9.0 | 0.3 ± 8.6 |
| beats per minute | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Change at Week 4 | 2.1 ± 11.0 | 0.1 ± 10.8 |
| Change at Week 12 | -0.5 ± 11.5 | -1.3 ± 10.2 |
| Change at Week 20 | -1.1 ± 10.3 | 1.1 ± 11.5 |
| Change at Week 22 | 1.3 ± 13.5 | -0.6 ± 11.3 |
| Change at Week 24 | 0.2 ± 13.0 | -1.8 ± 11.8 |
| Participants | Placebo | EvoMab 420 mg QM |
|---|---|---|
| Binding antibody positive at anytime | — | 0 |
| Neutralizing antibody positive at anytime | — | 0 |
| ng/mL | EvoMab 420 mg QM |
|---|---|
| Week 12 | 22400 ± 14700 |
| Week 22 | 64900 ± 34400 |
| Week 24 | 25800 ± 19200 |
Collected over Fatal AEs: from first dose date to end of study date (Week 24); non-fatal AEs: from first dose of study drug up to 30 days after last dose or end of study date, whichever was earlier. Mean (SD) duration on study was 5.664 (0.278) and 5.608 (0.137) months for the Placebo and EvoMab arms, respectively.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo SC QM | 0/53 (0%) | 0/53 (0%) | 19/53 (35.8%) |
| EvoMab 420 mg SC QM | 0/105 (0%) | 1/104 (1%) | 41/104 (39.4%) |
| Event | Placebo SC QM | EvoMab 420 mg SC QM |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/53 | 1/104 |
| Event | Placebo SC QM | EvoMab 420 mg SC QM |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/53 | 12/104 |
| HeadacheNervous system disorders | 1/53 | 11/104 |
| GastroenteritisInfections and infestations | 4/53 | 5/104 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/53 | 7/104 |
| InfluenzaInfections and infestations | 2/53 | 6/104 |
| Upper respiratory tract infectionInfections and infestations | 1/53 | 6/104 |
| PyrexiaGeneral disorders | 3/53 | 3/104 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/53 | 2/104 |
| RhinitisInfections and infestations | 2/53 | 0/104 |
| Blood creatine phosphokinase increasedInvestigations | 2/53 | 1/104 |
Full Analysis Set: participants who were randomized and dosed.
| Age, Continuous(years) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| Mean | 13.7 ± 2.5 | 13.7 ± 2.3 | 13.7 ± 2.4 |
| Sex: Female, Male(Participants) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| Female | 27 | 61 | 88 |
| Male | 26 | 43 | 69 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 13 |
| Not Hispanic or Latino | 46 | 98 | 144 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| Asian | 0 | 2 | 2 |
| Black (or African American) | 0 | 2 | 2 |
| White | 44 | 89 | 133 |
| Other, Not Specified | 9 | 11 | 20 |
| Stratification Factor: Age Group(participants) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| < 14 years | 25 | 48 | 73 |
| ≥ 14 years | 28 | 56 | 84 |
| Stratification Factor: Screening LDL-C Level(participants) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| < 160 mg/dL | 16 | 33 | 49 |
| ≥ 160 mg/dL | 37 | 71 | 108 |
| LDL-C(mg/dL) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| Mean | 183.0 ± 47.2 | 185.0 ± 45.0 | 184.3 ± 45.6 |
| Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)(mg/dL) | Placebo | EvoMab 420 mg QM | Total |
|---|---|---|---|
| Mean | 200.2 ± 48.2 | 203.8 ± 47.3 | 202.6 ± 47.5 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2016 to primary completion in Nov 2019, 44 months.
Results were first posted in Jul 2020, 7 months after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 44 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab